A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Registry ID

EUCTR2015-000452-24

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

AbbVie Deutschland GmbH & Co. KG

Start date

2017-01-26

Completion date

2019-10-15

Last update

2026-08-16

Conditions

• Hepatitis C Virus

Summary

To: - Assess the durability of response for subjects who achieved SVR12 with a regimen including ABT-493 and/or ABT-530. - Assess the emergence and persistence of specific HCV amino acid variants associated with drug resistance in subjects who experience virologic failure.

Locations

• , , Belgium
• , , Germany

Related clinical trials

• Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening

View on source registry